GREY:NEPTF - Post by User
Comment by
JayB1on Apr 19, 2011 8:09am
199 Views
Post# 18451401
RE: RE: RE: APO +25%
RE: RE: RE: APO +25%Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and SecondaryEndpoints with Statistically Significant Reductions in Triglycerides atBoth 4 Gram and 2 Gram Doses and Statistically Significant Decrease inLDL-C
Here is a link to Amarin news
https://investor.amarincorp.com/releasedetail.cfm?ReleaseID=569648